[ad_1]
The director of the Butantan Institute, Dimas Covas, said today that “sand the vaccination against covid-19 in Brazil begins in January, the fall in the number of cases and deaths from the disease should only be felt in April “.
“Starting in April, we will begin to see the effects of vaccination because we will have around 40 million people vaccinated,” he said. “As we get vaccinated, we will see if the pandemic decreases, if the cases decrease or if there will be herd immunity,” he said, at an event at the Claretian University Center in Batatais, in the interior of São Paullo.
Dimas Covas said that the effects of vaccination are not immediate and that it is necessary to advance in the immunization of other groups, in addition to the priority ones: “There are almost 100 million doses only for the elderly and health professionals. It is a relatively small range. expand to see if the vaccine is efficient, “he said.
The Butantan Institute will produce the CoronaVac vaccine in Brazil, developed in partnership with the Chinese laboratory Sinovac.
Previously, the Ministry of Health reported that it closed an agreement with Butantan to distribute vaccines against the new coronavirus exclusively by SUS (Unified Health System) to all states, simultaneously.
Anvisa emergency use request
Yesterday, Butantan made a request for emergency use to Anvisa (National Health Surveillance Agency) to apply doses of CoronaVac, emergency use is one that allows the application of doses in risk groups such as indigenous people, health professionals and the elderly .
The review of the documents, the first stage for the launch of the vaccine, was completed by Anvisa, who said data from Butantan are missing. According to the agency, the laboratory did not provide the expected documents.
This analysis carried out by Anvisa is the initial stage, it serves to check, in the first 24 hours, if there are essential documents on efficacy and clinical results among the orders.
Among the documents that Butantan could not deliver, according to Anvisa, are the data on the immunogenicity of the phase 3 study, that is, on the ability of the drug to give an immune response.
